Additionally, mice receiving serial tumor grafts and tumors originating from higher passages exhibited increased chemotherapy resistance, as manifested by activation of the AKT/PKB and Bcl‐2 pathways.[4] Anti‐VEGF antibody (bevacizumab) plus immune checkpoint inhibitor anti‐PDL1 antibody (atezolizumab) used in a clinical trial greatly extended HCC patient survival[5] compared to almost all other HCC treatments, indicating novel combination therapies may open up the tightly packed HCC tissues to make HCCs more vulnerable to immunotherapy. The gene discussed is AKT1; the disease is neoplasm.